LAKEWOOD, Colo.--(BUSINESS WIRE)--Terumo BCT announced today that the Spectra Optia system mononuclear cell (MNC) collection protocol is now cleared by the U.S. Food and Drug Administration (FDA) and ...
The Spectra Optia Apheresis System (Terumo BCT) is an apheresis and cell collection platform which can be used in the treatment of sickle cell disease. The purpose of this evaluation is to assess the ...
Bermuda Hospitals Board has unveiled a new machine to vastly improve its service for sickle-cell patients. The Spectra Optia therapeutic apheresis machine, which extracts and filters blood, was bought ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback